Switzerland · Delayed Price · Currency is CHF Ypsomed Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Management outlined a strategic shift to a pure-play injection device business, driven by strong growth in injectables, biosimilars, and GLP-1 therapies. Financial targets include doubling sales by 2030, maintaining high margins, and expanding global production, with risks mainly in execution and market volatility.
-
Strong H1 results driven by 21% core sales growth, 32.4% EBIT margin, and strategic focus on B2B injection devices. Guidance for 20% annual sales growth and >30% EBIT margin is confirmed, with major capacity expansion and innovation underway.
Fiscal Year 2025
-
Exceeded sales and profitability targets with 37% revenue growth, driven by delivery systems and global capacity expansion. Divestment of diabetes care and strong project pipeline position the company for 20% growth and higher EBIT next year.
-
A CHF 420 million deal to divest the Diabetes Care business to TecMed AG will transform the company into a pure-play injection system specialist, with proceeds funding core business expansion and no special dividend planned. The transaction includes an earn-out tied to sales, continued contract manufacturing, and significant operational shifts in Solothurn and Burgdorf.
-
Strong revenue and EBIT growth driven by delivery systems and diabetes care, with continued global expansion and a solid balance sheet. Strategic divestments and a robust project pipeline support a positive outlook, with guidance reaffirmed for 25% top-line growth and CHF 140 million EBIT.